High-volume injection in the management of recalcitrant mid-body Achilles tendinopathy: a prospective case series assessing the influence of neovascularity and outcome
International Musculoskeletal Medicine · 2012-09 · 34 (3) · 92-100
DOI: 10.1179/1753615412y.0000000004 ↗At a glance
Journal article in International Musculoskeletal Medicine, published online on 2013-07-18. Written by Peter Resteghini and 1 co-authors. Cited 15 times so far (Crossref); 43 references.
Abstract (original language)
ObjectivesTo determine the effectiveness of ultrasound-guided high-volume injection (HVI) and relevance of neovascularity on outcome in Achilles tendinopathy.MethodsThis prospective clinical study at the Homerton University Hospital included 32 patients with recalcitrant unilateral mid-substance Achilles tendinopathy. Outcome measures used were Victorian Institute of Sport Assessment-Achilles tendon (VISA-A), Visual Analogue Score (VAS), modified Öhberg score and mean maximum tendon thickness.ResultsSignificant improvements in both VAS and VISA-A scores at 1 month (95% confidence interval (CI), 6.6–3.2, P < 0.001 and 37.2–63.7, P < 0.001). This improvement was maintained at 3 months (95% CI, 6.6–2.9, P < 0.001 and 37.2–65.9, P < 0.001). Symptomatic tendons were significantly thicker at baseline than the asymptomatic side (95% CI, 8.3 mm compared to 5.9 mm, P < 0.001). There was a significant decrease in maximum tendon thickness in the symptomatic tendons at baseline and at 3 months (95% CI, 8.3–7.6 mm, P < 0.001). Mean Öhberg neovascularity scores demonstrated a significant decrease between baseline and 3 month review (95% CI, 2.5–1.1, P < 0.001). There was a significant difference in neovascularity at baseline for the symptomatic and asymptomatic sides (95% CI, 2.5 compared to 0.2, P < 0.001). There was a positive correlation between baseline neovascularity and difference in VAS scores at baseline and 3 months. Patients with higher baseline Öhberg scores demonstrated a more positive outcome (95% CI, correlation coefficient 0.696, P < 0.01).DiscussionUltrasound-guided HVI is safe and clinically cost-effective in treating Achilles tendinopathy. Results suggest that baseline neovascularity is relevant to outcome following injection.
Cite
APA
Resteghini, P., & Yeoh, J. (2012). High-volume injection in the management of recalcitrant mid-body Achilles tendinopathy: a prospective case series assessing the influence of neovascularity and outcome. International Musculoskeletal Medicine, 34(3), 92-100. https://doi.org/10.1179/1753615412y.0000000004
Vancouver
Resteghini P, Yeoh J. High-volume injection in the management of recalcitrant mid-body Achilles tendinopathy: a prospective case series assessing the influence of neovascularity and outcome. International Musculoskeletal Medicine. 2012;34(3):92-100. doi:10.1179/1753615412y.0000000004
BibTeX
@article{Resteghini2012,
author = {Resteghini, Peter and Yeoh, Justin},
title = {High-volume injection in the management of recalcitrant mid-body Achilles tendinopathy: a prospective case series assessing the influence of neovascularity and outcome},
journal = {International Musculoskeletal Medicine},
year = {2012},
volume = {34},
number = {3},
pages = {92--100},
doi = {10.1179/1753615412y.0000000004}
}
EUVIMED